Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.

Babicky ML, Harper MM, Chakedis J, Cazes A, Mose ES, Jaquish DV, French RP, Childers B, Alakus H, Schmid MC, Foubert P, Miyamoto J, Holman PJ, Walterscheid ZJ, Tang CM, Varki N, Sicklick JK, Messer K, Varner JA, Waltz SE, Lowy AM.

Oncogene. 2019 Jul;38(28):5599-5611. doi: 10.1038/s41388-019-0811-9. Epub 2019 Apr 9.

2.

Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.

Cheng J, Okolotowicz KJ, Ryan D, Mose E, Lowy AM, Cashman JR.

Am J Cancer Res. 2019 Feb 1;9(2):390-405. eCollection 2019.

3.

p190-B RhoGAP and intracellular cytokine signals balance hematopoietic stem and progenitor cell self-renewal and differentiation.

Hinge A, Xu J, Javier J, Mose E, Kumar S, Kapur R, Srour EF, Malik P, Aronow BJ, Filippi MD.

Nat Commun. 2017 Feb 8;8:14382. doi: 10.1038/ncomms14382.

4.

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.

Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy AM.

Oncotarget. 2016 Jul 19;7(29):45959-45975. doi: 10.18632/oncotarget.10009.

5.

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA.

Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13.

6.

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.

Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z, Lowy AM.

Oncogene. 2016 Jun 23;35(25):3249-59. doi: 10.1038/onc.2015.384. Epub 2015 Oct 19.

7.

Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 Jul 26;6(7):53. doi: 10.1186/s13073-014-0053-y. eCollection 2014. No abstract available.

8.

Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 May 29;6(5):43. doi: 10.1186/gm559. eCollection 2014.

9.

Differential eosinophil and mast cell regulation: mast cell viability and accumulation in inflammatory tissue are independent of proton-sensing receptor GPR65.

Zhu X, Mose E, Hogan SP, Zimmermann N.

Am J Physiol Gastrointest Liver Physiol. 2014 Jun 1;306(11):G974-82. doi: 10.1152/ajpgi.00341.2013. Epub 2014 Apr 17.

10.

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor.

Sicklick JK, Leonard SY, Babicky ML, Tang CM, Mose ES, French RP, Jaquish DV, Hoh CK, Peterson M, Schwab R, Lowy AM.

J Transl Med. 2014 Feb 10;12:41. doi: 10.1186/1479-5876-12-41.

11.

Proton channel HVCN1 is required for effector functions of mouse eosinophils.

Zhu X, Mose E, Zimmermann N.

BMC Immunol. 2013 May 24;14:24. doi: 10.1186/1471-2172-14-24.

12.

A dual-color genetically engineered mouse model for multispectral imaging of the pancreatic microenvironment.

Snyder CS, Harrington AR, Kaushal S, Mose E, Lowy AM, Hoffman RM, Bouvet M.

Pancreas. 2013 Aug;42(6):952-8. doi: 10.1097/MPA.0b013e31828643df. Erratum in: Pancreas. 2013 Oct;42(7):1199.

13.

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, Weems JM, Park FD, Mose E, Wang Y, Hoffman RM, Lowy AM, Bouvet M, Klemke RL.

Cancer Res. 2012 May 15;72(10):2554-64. doi: 10.1158/0008-5472.CAN-11-3552.

14.

The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, Niessen S, Hoover H, Shields D, Cheresh D, Cravatt BF, Lowy AM.

Int J Cancer. 2012 Oct 15;131(8):1744-54. doi: 10.1002/ijc.27447. Epub 2012 Mar 8.

15.

Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM.

Cancer Res. 2010 Feb 1;70(3):1130-40. doi: 10.1158/0008-5472.CAN-09-0761. Epub 2010 Jan 26.

16.

Expression of melanocyte-related genes in human breast cancer and its implications.

Montel V, Suzuki M, Galloy C, Mose ES, Tarin D.

Differentiation. 2009 Dec;78(5):283-91. doi: 10.1016/j.diff.2009.07.007. Epub 2009 Aug 21.

PMID:
19699574
17.

Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts.

Suzuki M, Mose E, Galloy C, Tarin D.

Am J Pathol. 2007 Aug;171(2):682-92. Epub 2007 Jul 9.

18.

Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency.

Suzuki M, Mose ES, Montel V, Tarin D.

Am J Pathol. 2006 Aug;169(2):673-81.

19.
20.

Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model.

Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D.

Am J Pathol. 2005 May;166(5):1565-79.

21.
22.

From the other side.

Mose EC.

JOGN Nurs. 1974 Mar-Apr;3(2):47-50. No abstract available.

PMID:
4493980

Supplemental Content

Support Center